- Home
- RIME vs MBRX Comparison
RIME vs MBRX Comparison
Compare RIME & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIME
- MBRX
- Stock Information
- Founded
- RIME 1982
- MBRX 2015
- Country
- RIME United States
- MBRX United States
- Employees
- RIME N/A
- MBRX N/A
- Industry
- RIME
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- RIME
- MBRX Health Care
- Exchange
- RIME NYSE
- MBRX Nasdaq
- Market Cap
- RIME 1.4M
- MBRX 1.4M
- IPO Year
- RIME 1994
- MBRX 2016
- Fundamental
- Price
- RIME $2.77
- MBRX $1.28
- Analyst Decision
- RIME
- MBRX Strong Buy
- Analyst Count
- RIME 0
- MBRX 2
- Target Price
- RIME N/A
- MBRX $24.00
- AVG Volume (30 Days)
- RIME 887.9K
- MBRX 13.3M
- Earning Date
- RIME 03-04-2025
- MBRX 03-21-2025
- Dividend Yield
- RIME N/A
- MBRX N/A
- EPS Growth
- RIME N/A
- MBRX N/A
- EPS
- RIME N/A
- MBRX N/A
- Revenue
- RIME $32,479,657.00
- MBRX N/A
- Revenue This Year
- RIME N/A
- MBRX N/A
- Revenue Next Year
- RIME N/A
- MBRX N/A
- P/E Ratio
- RIME N/A
- MBRX N/A
- Revenue Growth
- RIME 11.81
- MBRX N/A
- 52 Week Low
- RIME $2.41
- MBRX $0.40
- 52 Week High
- RIME $394.00
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- RIME N/A
- MBRX 46.92
- Support Level
- RIME N/A
- MBRX $1.55
- Resistance Level
- RIME N/A
- MBRX $2.22
- Average True Range (ATR)
- RIME 0.00
- MBRX 0.50
- MACD
- RIME 0.00
- MBRX 0.08
- Stochastic Oscillator
- RIME 0.00
- MBRX 27.12
About RIME ALGORHYTHM HOLDINGS INC
Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.